WEO Media vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Dental marketing agency providing websites, SEO, PPC, and patient communication for dental practices in the US and Canada. Beaverton OR; founded 2009;
About
WEO Media is a Beaverton, Oregon-based dental-specific marketing agency and technology company that provides website design, search engine optimization, pay-per-click advertising, online reputation management, and patient communication tools to dental practices across the United States and Canada. Founded in 2009, WEO Media built its business around the unique marketing needs of independent dental practices and DSO-affiliated offices, which differ significantly from general small business marketing in their emphasis on local search visibility, treatment-specific landing pages, patient reviews, and HIPAA-compliant communication. The company combines managed digital marketing services with proprietary technology tools for patient communication and review generation, offering dental practices a full-service growth marketing partner.\n\nWEO Media's website platform is purpose-built for dental practices, with built-in features for treatment page templates, appointment request forms, before-and-after gallery management, and ADA accessibility compliance. The company's SEO methodology focuses on local search dominance—ensuring that each dental practice ranks prominently for high-intent searches like "dentist near me," "dental implants [city]," and "emergency dentist [neighborhood]"—which drives the majority of new patient acquisition for most dental offices. WEO Media manages Google Business Profiles, local citation building, and online review acquisition campaigns as integrated components of its local SEO service.\n\nWEO Media targets independent dental practices and small group practices that want to outsource their digital marketing to a specialist with deep dental industry knowledge rather than working with a general digital marketing agency that lacks familiarity with dental treatment marketing, HIPAA compliance requirements, and the competitive dynamics of local dental markets. The company competes with ProSites, TNT Dental, and PatientSites in the dental marketing agency space, as well as with in-house marketing capabilities at larger DSOs. WEO Media differentiates on its combination of managed services and proprietary technology and its long track record in the dental market.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.